Cargando…
RITA displays anti-tumor activity in medulloblastomas independent of TP53 status
Current therapy of medulloblastoma, the most common malignant brain tumor of childhood, achieves 40–70% survival. Secondary chemotherapy resistance contributes to treatment failure, where TP53 pathway dysfunction plays a key role. MDM2 interaction with TP53 leads to its degradation. Reactivating TP5...
Autores principales: | Gottlieb, Aline, Althoff, Kristina, Grunewald, Laura, Thor, Theresa, Odersky, Andrea, Schulte, Marc, Deubzer, Hedwig E., Heukamp, Lukas, Eggert, Angelika, Schramm, Alexander, Schulte, Johannes H., Künkele, Annette |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5438615/ https://www.ncbi.nlm.nih.gov/pubmed/28427187 http://dx.doi.org/10.18632/oncotarget.15840 |
Ejemplares similares
-
BET bromodomain protein inhibition is a therapeutic option for medulloblastoma
por: Henssen, Anton, et al.
Publicado: (2013) -
The GSK461364 PLK1 inhibitor exhibits strong antitumoral activity in preclinical neuroblastoma models
por: Pajtler, Kristian W, et al.
Publicado: (2016) -
Reactivating TP53 signaling by the novel MDM2 inhibitor DS-3032b as a therapeutic option for high-risk neuroblastoma
por: Arnhold, Viktor, et al.
Publicado: (2017) -
The KDM1A histone demethylase is a promising new target for the epigenetic therapy of medulloblastoma
por: Pajtler, Kristian W, et al.
Publicado: (2013) -
Sinusoidal Obstruction Syndrome Following Myeloablative Therapy and Tranexamic Acid Treatment for Hemorrhage in Two Patients with Neuroblastoma
por: Zirngibl, Felix, et al.
Publicado: (2020)